UPDATE 1-Belgium's UCB to buy Ra Pharmaceuticals in $2.1 bln cash deal

UCB has agreed to acquire U.S.-based Ra Pharmaceuticals for $2.1 billion, both companies reported on Thursday, in a deal that will enable the Belgian drugmaker to offer new treatment opportunities for several rare diseases in neurology and immunology. “Ra Pharma is an excellent strategic fit addressing multiple areas of UCB’s patient value growth strategy,” UCB’s Chief Executive Officer Jean-Christophe Tellier said in a joint statement. The acquisition of the clinical-stage biopharmaceutical company, which was founded in 2008, is expected to contribute to UCB’s core earning per share and increase its revenue and net profit from 2024 onwards.

Source:: Yahoo! Trucking News